Tombesi Paolo
EVP & Chief Financial Officer at Turning Point Therapeutics, Inc.; Chief Financial Officer at Epizyme, Inc.
- Sold, on record
- $148k
- Dollars the filings state
- Form 4 sales
- 4
- Latest Jul 27, 2022
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- Turning Point Therapeutics, Inc.EVP & Chief Financial Officer
- Epizyme, Inc.Chief Financial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Epizyme, Inc.4,069 shares
- Turning Point Therapeutics, Inc.1,183 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Epizyme, Inc.Plan not statedMar 25, 2020 2020
Sold 1,243 shares at $15.28 ($19k)
Tombesi Paolo, Chief Financial Officer
Sold 7.5% of holdings ($255k position)15,437 shares leftFirst sale on recordFiling
- 2 Form 4 sale Epizyme, Inc.Plan not statedJun 26, 2020 +93 days
Sold 1,805 shares at $16.15 ($29k)
Tombesi Paolo, Chief Financial Officer
Sold 7.6% of holdings ($384k position)21,942 shares leftFiling
- 3 Form 4 sale Epizyme, Inc.Plan not statedFeb 4, 2021 +223 days
Sold 1,021 shares at $11.21 ($11k)
Tombesi Paolo, Chief Financial Officer
Sold 1.9% of holdings ($611k position)53,465 shares leftFiling
- 4 Form 4 sale Turning Point Therapeutics, Inc.Plan not statedJul 27, 2022 +538 days
Sold 1,183 shares at $74.94 ($89k)
Tombesi Paolo, EVP & Chief Financial Officer
Sold 4% of holdings ($2.2M position)28,700 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (4)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2022 | Jul 29, 2022 | Turning Point Therapeutics, Inc. | EVP & Chief Financial Officer | Form 4 sale | 1,183 | $89k | 4.0% | Plan not stated | SEC |
| Feb 4, 2021 | Feb 5, 2021 | Epizyme, Inc. | Chief Financial Officer | Form 4 sale | 1,021 | $11k | 1.9% | Plan not stated | SEC |
| Jun 26, 2020 | Jun 30, 2020 | Epizyme, Inc. | Chief Financial Officer | Form 4 sale | 1,805 | $29k | 7.6% | Plan not stated | SEC |
| Mar 25, 2020 | Mar 26, 2020 | Epizyme, Inc. | Chief Financial Officer | Form 4 sale | 1,243 | $19k | 7.5% | Plan not stated | SEC |